The aim of this study is to show that a preemptive treatment by ganciclovir (for positive CMV viremia) or aciclovir (for positive HSV oro-pharyngeal PCR) is able to increase the number of ventilator-free days at Day 60.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
317
Intravenous 15 mg/kg/d during 14 days
intravenous 10 mg/kg/d for 14 days
Assistance Publique - Hôpitaux de Marseille
Marseille, France
Ventilator-free days at Day 60
Time frame: 60 days
Day 60 mortality
Time frame: 60 days
ICU mortality
Time frame: 60 days
Hospital mortality
Time frame: 60 days
Duration of mechanical ventilation in survivors
Time frame: 60 days
Duration of ICU stay
Time frame: 60 days
Duration of hospital stay
Time frame: 60 days
Incidence of ventilator-associated pneumonia
Time frame: 60 days
Incidence of bacteremia
Time frame: 60 days
SOFA score
Time frame: days 3, 5, 7, 14, 21 and 28
Acute renal failure related to aciclovir or its placebo
Time frame: 60 days
Leucopenia related to ganciclovir or its placebo
Time frame: 60 days
Time to oropharyngeal negativation of HSV PCR
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time to blood negativation of CMV PCR
Time frame: 30 days
Incidence of herpetic bronchopneumonia
Time frame: 60 days
Incidence of active CMV infection
Time frame: 60 days